GIOncologist @IUCancerCenter via #WashUOnc, #PittGIM | Precision-Oncology, Colorectal Cancer, Carnatic music vocalist/enthusiast | 🇮🇳🇺🇸 | tweets are mine
Joined January 2022
- Tweets26
- Following82
- Followers28
- Likes184
Susrutha Puthanmadhom Narayanan retweeted
Original Article: Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer nej.md/4f7xfhX
Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer nej.md/4neOTCE
#Oncology #Gastroenterology
ALT Figures showing survival in patients with RAS G12–mutated and all-RAS-mutated PDAC.
Susrutha Puthanmadhom Narayanan retweeted
"Medicine was not something I did between 9 AM and 5 PM. It was not something that sat on one side of a scale opposite of 'life.' Medicine was woven through every aspect of my life."
In #APieceofMyMind, a retired family physician reflects on the boxes of paper left behind by a medical career—and the enduring relationships, lessons, and identity they represent.
ja.ma/4cH5iuJ
Susrutha Puthanmadhom Narayanan retweeted
Amivantamab in mCRC, hot off the presses
3rd line + chemo-refractory mCRC
Terrible disease, great signal
OrigAMI-1 (phase 1/2):
• RAS/BRAF WT, HER2–
• 2–3 prior lines
• n=94
Efficacy:
• ORR:
– 29% (EGFR-naive, left)
– 19% (post–EGFR, left)
– 22% (right-sided)
• PFS: ~3.7–5.7 mo
• DoR: ~6–10 mo
Signal holds across:
• prior EGFR exposure
• sidedness
Rechallenge signal:
• longer interval from prior EGFR → higher ORR (~32%)
Toxicity:
• Rash / dermatitis (expected)
• Infusion reactions common
• Low discontinuation
Phase 1 always overestimates.
But…
These response rates are not typical for this setting.
If PFS holds in phase 3, this changes practice quickly.
And yes, I’m already filling out compassionate use forms on my patient’s behalf.
Full Article:
ascopubs.org/doi/pdfdirect/1…
@OncoAlert @TheGutOncLab @Onco_Nexus
Susrutha Puthanmadhom Narayanan retweeted
A recent study provides proof of principle that a single genetic edit can overcome the effect of nonsense variants in different genes, akin to a one-size-fits-many model.
Learn more in the Clinical Implications of Basic Research article “Editing tRNA Genes to Broaden Nonsense Therapeutics” by John D. Lueck, PhD (@littlelueck), from the University of Rochester School of Medicine and Dentistry (@URochester_SMD): nejm.org/doi/full/10.1056/NE…
ALT A figure showing variant-specific genome editing versus disease-agnostic prime editing to generate a suppressor tRNA.
Susrutha Puthanmadhom Narayanan retweeted
A MUST-READ!
This is probably one of my most important papers where I try to teach how to fish rather than offer fish.
How I Read a Clinical Trial Report?
BG’s primer for Busy Clinicians.
Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.
ascopubs.org/doi/10.1200/OP-…
Susrutha Puthanmadhom Narayanan retweeted
For decades, biology textbooks have enshrined a simple rule: DNA is made by copying a template. After one enzyme unzips a DNA double helix into separate strands, another called a polymerase builds a complementary sequence, base by base, for each strand. Presto: two copies of the original DNA.
But new research into how bacteria defend themselves from viruses now shows this synthesis rule isn’t absolute.
Now, a team describes a bacterial enzyme that synthesizes DNA without a nucleic acid template, using its own structure as a guide.
Learn more: scim.ag/4tTc5IA @NewsfromScience
Susrutha Puthanmadhom Narayanan retweeted
Nature research paper: Emergence of oncofetal plasticity is ubiquitous in early colorectal cancers
go.nature.com/4cMwlWA
Susrutha Puthanmadhom Narayanan retweeted
🚨 Up to 40% of rectal cancer patients may not need surgery.
In dMMR disease (with proper testing)
Immunotherapy → ~90-100% CR
In MSS
TNT: ~1 in 3 achieve cCR
With watch-and-wait:
~85% keep their rectum
>95% remain metastasis-free
Local regrowth ~15%, mostly detected early and successfully salvaged
It’s smarter upfront intensification then personalized decisions.
But this isn’t a simple algorithm.
It requires clinical judgment, proper testing, careful selection and intensive surveillance.
What once seemed unthinkable is now part of evolving clinical practice; the state of the art care
thelancet.com/journals/eclin…
Susrutha Puthanmadhom Narayanan retweeted
Nature research paper: Atlas-guided discovery of transcription factors for T cell programming
go.nature.com/4afm6b5
Susrutha Puthanmadhom Narayanan retweeted
Just out, our study examining gene expression differences between ILC and IDC/NST breast cancers showing consistent increases in cAMP/PKA/CREB signaling, potential for targeting?
bit.ly/3C5Sn70
@UPMCHillmanCC @MageeWomens @BCRFcure @SusanGKomen #lobular
Susrutha Puthanmadhom Narayanan retweeted
Presented at #ASCO24:
Among patients with EGFR-mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as compared with 13% of those who received placebo. Full LAURA trial results: nej.md/451OXwi
ALT Page 1 of the Original Article "Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC."
Susrutha Puthanmadhom Narayanan retweeted
Fellows across all three years had the opportunity to attend #ASCO24 (and enjoy the beautiful Chicago weather!)
Susrutha Puthanmadhom Narayanan retweeted
You won't want to miss the next #TIPS Seminar on February 7 when we hear about #WUPhysicianScientist Dr. Susrutha Narayanan's interesting patient! Zoom link here: physicianscientists.wustl.ed…
Susrutha Puthanmadhom Narayanan retweeted
Online Now: Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer dlvr.it/T1PyK7
Susrutha Puthanmadhom Narayanan retweeted
🙌 Osimertinib + chemotherapy enhances CNS efficacy vs osimertinib alone in EGFRm advanced non small-cell #LungCancer ➡️ brnw.ch/21wFOmm #LCSM @dplanchard
Susrutha Puthanmadhom Narayanan retweeted
Early stage NSCLC has been evolving in real time over the past few years, w/ multiple key trials of neoadjuvant &/or adjuvant therapy trials incorporating targeted therapy or immunotherapy; this review summarizes data & recs for current clinical practice. ja.ma/4aFjmmO
Susrutha Puthanmadhom Narayanan retweeted
🙌 Prospective study of chemo-free treatment with pembro + RT for biomarker-selected locally advanced non-small cell #LungCancer ➡️ brnw.ch/21wFHxj #LCSM #ImmunoOnc @nitinohri @DrSteveMartin
Susrutha Puthanmadhom Narayanan retweeted
JAMA Internal Medicine introduces a new series, the Guide to Statistics and Methods, to be accessible to clinicians and researchers contextualizing and interpreting statistical methods applied in studies published in JAMA Internal Medicine. ja.ma/3uLFDig
Susrutha Puthanmadhom Narayanan retweeted
From our recently published paper
-Â low neighborhood SES is associated with worse outcomes in patients with metastatic breast cancer
Susrutha Puthanmadhom Narayanan retweeted
In patients with lung cancer, neoadjuvant treatment with nivolumab and chemotherapy resulted in a significantly higher percentage of patients with a pathological complete response than chemotherapy alone. nej.md/3pjpj63